BioSpace News Archive

ransparent plastic tube being blocked by orange balls on blue background. Illustration of the concept of digestive disorders and difficulties on career paths

Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.

March 31, 2026

·

2 min read

·

Tristan Manalac

Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.

Immunology and inflammation

Viridian Turns Red as Thyroid Eye Disease Data Disappoint

Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that analysts had been hoping for, and the biotech’s stock price fell by one-third.

March 31, 2026

·

2 min read

·

Tristan Manalac

Red alarm clock on dollar banknotes. Retro style alarm clock and dollars. Time to work / tome to make money concept.

Mergers & acquisitions

Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda

In the buyout, Eli Lilly picks up Centessa Pharmaceuticals’ lead asset cleminorexton, which could go toe-to-toe with Takeda’s oveporexton, currently under FDA review with a decision expected in the third quarter.

March 31, 2026

·

2 min read

·

Tristan Manalac

Immunology and inflammation

AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases

Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of next-generation skin drugs but also shed light on how they might fare on the market.

March 31, 2026

·

4 min read

·

Tristan Manalac

Illustration showing a downward graph trend

Rare diseases

PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease

PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.

March 31, 2026

·

2 min read

·

Heather McKenzie

Businessman in starting position ready to sprint run stock illustration

Mergers & acquisitions

Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy

In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.

March 31, 2026

·

4 min read

·

Annalee Armstrong

Press Releases

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 31, 2026

·

19 min read

Press Releases

DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights